




The relative strengths and weaknesses of Relmada Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Relmada Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Relmada Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 74% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	45,796
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,291
Liabilities, Non-Current	0
Other Assets	22
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	4.5
Other Net Income	3,912
Other Revenues	0
Property and Equipment	0
Research and Development	46,176
Selling, General and Administrative Expense	37,716

Output Variable	Value in 1000 USD
Assets	45,818
Liabilities	10,296
Expenses	83,891
Revenues	0
Stockholders Equity	35,522
Net Income	-79,979
Comprehensive Net Income	-79,979
BaseVar	71,958
ECR before LimitedLiability	-9.1%
Economic Capital Ratio	141%